The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
 
Heather A. Wakelee
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst); Xcovery (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck
 
Moishe Liberman
Stock and Other Ownership Interests - AssistIQ; Ditch Labs; Endocision
Consulting or Advisory Role - Johnson and Johnson
Patents, Royalties, Other Intellectual Property - Cryobiopsy Device
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Takeda
Consulting or Advisory Role - AstraZeneca; BeiGene; DaiichiSankyo; Janssen; Merck Serono; MSD; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); BMG Inc (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb KK (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck; Roche
Consulting or Advisory Role - AstraZeneca; BMS/Ono; IMBdx; Janssen; Lilly; Merck; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Lunit; Merck
Travel, Accommodations, Expenses - Novartis
 
Jie He
No Relationships to Disclose
 
Shugeng Gao
No Relationships to Disclose
 
Ke-Neng Chen
No Relationships to Disclose
 
Christophe Alfons Dooms
No Relationships to Disclose
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Roche
 
Ekkehard Eigendorff
Honoraria - Boehringer Ingelheim; Merck; MSD; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Merck; MSD; Roche
Speakers' Bureau - Boehringer Ingelheim; Merck; MSD; Roche
 
Gaston Lucas Martinengo
No Relationships to Disclose
 
Olivier Bylicki
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; MSD; Roche; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; MSD
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Flame Biosciences; Genentech/Roche; Guardant Health; Janssen Oncology; Merck; Novartis; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Silvia Novello
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Jing Yang
Employment - Merck
 
Steven M. Keller
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Ayman Samkari
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Jonathan Spicer
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Medarex; Chemocentryx; Merck; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck; Protalix Biotherapeutics; Regeneron; Xenetic Biosciences
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Medarex (Inst); CLS-Therapeutics (Inst); CLS-Therapeutics (Inst); Merck (Inst); Protalix Biotherapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck